Immunology
Temporal Arteritis
14
Pipeline Programs↗
0
Active Trials↗
7
Companies Involved↗
Temporal Arteritis is an emerging landscape with 14 programs across 7 companies. The most active players are Johnson & Johnson, Bristol-Myers Squibb, Novartis. 5 therapies are approved with 6 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 36
Analysis
Modality Breakdown
14programs
Small molecule750%
Monoclonal antibody643%
Protein / enzyme17%
Modality classified for 100% of 14 pipeline programs.
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)